Benjamin Capoccia
Washington University in St. Louis
H-index: 17
North America-United States
Top articles of Benjamin Capoccia
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Therapeutic sirp-alpha antibodies | 2023/9/7 | ||
Methods for identifying biomarkers to predict treatment response | 2022/6/16 | ||
Combination therapy for the treatment of solid and hematological cancers | 2022/10/6 | ||
AO-176, a differentiated clinical-stage anti-CD47 antibody, demonstrates potent anti-tumor activity across multiple preclinical models of b cell neoplasms | Blood | William Casey Wilson John O Richards Gabriela Andrejeva Benjamin J Capoccia Robyn J Puro | 2021/11/23 |
260 CD47 antibody, AO-176 demonstrates potent anti-tumor activity in pre-clinical solid tumor xenografts as a single agent and in combination with multiple classes of therapeutics | Journal for ImmunoTherapy of Cancer | Gabriela Andrejeva Benjamin Capoccia Rachel Delston Michael Donio Ronald Hiebsch | 2021/11/1 |
Biomarkers to improve efficacy of cancer immunotherapy | 2021/12/23 | ||
Anticorpo monoclonal, ou fragmento de ligação ao antígeno do mesmo; anticorpo biespecífico; método para prevenir ou tratar um câncer suscetível em um ser humano; método de … | 2021/9/14 | ||
AO-176, a highly differentiated clinical stage anti-CD47 antibody, is efficacious in pre-clinical models of lymphoma | Cancer Research | Benjamin J Capoccia Michael J Donio John O Richards Ronald R Hiebsch Robyn J Puro | 2021/7/1 |
Novel SIRPα antibodies that induce single-agent phagocytosis of tumor cells while preserving T cells | The Journal of Immunology | Gabriela Andrejeva Benjamin J Capoccia Ronald R Hiebsch Michael J Donio Isra M Darwech | 2021/2/15 |
Therapeutic SIRP-α antibodies | 2021/12/21 | ||
215 AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin | Robyn Puro Prabir Chakraborty John Richards Ronald Hiebsch Michael Donio | 2020/11/1 | |
THERAPEUTIC SIRPα ANTIBODIES | 2020/5/22 | ||
Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anticancer properties and negligible red blood cell binding | Molecular Cancer Therapeutics | Robyn J Puro Myriam N Bouchlaka Ronald R Hiebsch Benjamin J Capoccia Michael J Donio | 2020/3/1 |
Pre-clinical combination of AO-176, a highly differentiated clinical stage CD47 antibody, with either azacitidine or venetoclax significantly enhances DAMP induction and … | Blood | Mike J Donio W Casey Wilson Isra Darwech Gabriela Andrejeva Benjamin J Capoccia | 2020/11/5 |
